Chargement en cours...
The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
OBJECTIVES: Preclinical studies showed that BRAF(V600E) mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy. However, clinical data regarding its role in therapeutic decision making with respect to RAI therapy are currently insufficient...
Enregistré dans:
| Publié dans: | Nucl Med Commun |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Lippincott Williams & Wilkins
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282664/ https://ncbi.nlm.nih.gov/pubmed/30312216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000930 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|